Nanocrystalline Megestrol Acetate to Help Appetite During Chemoradiotherapy in Nasopharyngeal Carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, phase III, randomized, double-blind, placebo-controlled study evaluating nanocrystalline megestrol acetate added to standard concurrent chemoradiotherapy (CCRT) for locally advanced nasopharyngeal carcinoma. Participants with newly diagnosed stage II-III NPC will be assigned 1:1 to receive either the active agent (5 ml/day) or placebo for 11 weeks alongside CCRT. The primary goal is to reduce clinically significant weight loss (>5% from baseline) by day 28 after radiotherapy, with secondary aims including improvements in appetite, quality of life, nutritional status, and overall survival outcomes. Safety and tolerability will also be monitored. Eligible patients are adults aged 18-70 with adequate organ function and ECOG 0-1.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed, histologically or cytologically confirmed non-keratinizing nasopharyngeal carcinoma, clinical stage II-III according to the American Joint Committee on Cancer (AJCC) 9th edition staging system, and planned to receive concurrent chemoradiotherapy (CCRT).
* No prior radiotherapy to the primary tumor.
* Induction chemotherapy may be administered at the investigator's discretion according to local guidelines.
* Aged 18-70 years, male or female.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
* Able to comply with the study procedures and voluntarily provide written informed consent.
* Adequate organ function, defined as follows:

  * Hematologic function: neutrophil count ≥1.5 × 10⁹/L, hemoglobin ≥90 g/L, and platelet count ≥100 × 10⁹/L.
  * Coagulation function: international normalized ratio (INR), prothrombin time (PT), or activated partial thromboplastin time (aPTT) ≤1.5 × the upper limit of normal (ULN).
  * Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN, total bilirubin ≤2.0 × ULN, and serum albumin ≥30 g/L.
  * Renal function: serum creatinine ≤1.5 × ULN or calculated creatinine clearance (CrCl) ≥60 mL/min using the Cockcroft-Gault formula.

Exclusion Criteria:

* Prior antitumor therapy, including chemotherapy, radiotherapy, or surgery, other than induction chemotherapy permitted according to the study protocol.
* Pregnant or breastfeeding women.
* Inability to comply with regular follow-up because of psychological, social, familial, or geographical factors.
* Concurrent participation in another clinical study involving investigational treatment during the study treatment period.
* Known allergy to any chemotherapeutic agent that may be used in the study.
* Severe uncontrolled infection or other serious uncontrolled medical illness.
* Major organ dysfunction, including decompensated cardiac, pulmonary, renal, or hepatic failure, that would preclude tolerance of chemoradiotherapy.
* Conditions that may substantially affect drug administration, distribution, metabolism, or excretion, including significant psychiatric disorders, central nervous system disorders, chronic diarrhea, ascites, or pleural effusion.
* Long-term use of immunosuppressive agents following organ transplantation.
* History of another malignancy before enrollment.
* Conditions affecting gastrointestinal absorption or oral intake, including dysphagia, malabsorption, or uncontrolled vomiting; difficulty with food intake or requirement for enteral or parenteral nutritional support; anorexia nervosa or anorexia related to psychiatric illness; or difficulty eating because of pain.
* Current or planned use of other medications that may increase appetite or body weight, including systemic corticosteroids (except short-term dexamethasone administered during chemotherapy), androgens, progestogens, thalidomide, olanzapine, anamorelin, or other appetite stimulants.
* Cushing syndrome, adrenal insufficiency, or pituitary insufficiency; poorly controlled diabetes mellitus; or uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite oral antihypertensive therapy.
* Thromboembolic disease, ascites, or lower-extremity edema within 6 months before the first dose of study treatment; history of esophageal or gastric varices, severe gastrointestinal ulceration, gastrointestinal perforation and/or fistula, gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), intra-abdominal abscess, or acute gastrointestinal bleeding.
* Known hypersensitivity to any component of the study drug.
* Any other condition that, in the investigator's judgment, would make the patient unsuitable for participation in the study.

Where it's running

• Sun Yat-sen University Cancer Cente
  Guangzhou, Guangdong, China Recruiting
• Hunan Cancer Hospital
  Changsha, China Recruiting
• Fujian Cancer Hospital
  Fuzhou, China Recruiting

Study contacts

• Study coordinator: Hai-Qiang Mai, PhD, MD
• Email: maihq@sysucc.org.cn
• Phone: +8602087343643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Becotatug Vedotin plus Anti-PD-1 as maintenance for recurrent/metastatic NPC

  This phase 3 trial tests whether adding becotatug vedotin to an anti-PD-1 therapy as maintenance can help people with recurrent or metastatic nasopharyngeal cancer who have stable disease after initial treatment.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07705243

• Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer

  This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.

  Recruiting Phase 1 West China Hospital · Chengdu, China · NCT07625423

• Maintenance immunotherapy with deferred salvage radiotherapy after response to chemoimmunotherapy in recurrent nasopharyngeal cancer

  This study tests whether continuing immunotherapy and delaying salvage radiotherapy after an initial chemoimmunotherapy response can help people with unresectable recurrent nasopharyngeal cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Fuzhou, Fujian and 3 other locations · NCT07528183

• Becotatug vedotin added to radiation and adjuvant therapy for locally advanced nasopharyngeal cancer with a poor response to induction chemo‑immunotherapy

  This will test whether adding becotatug vedotin during radiation and afterward helps people with locally advanced nasopharyngeal cancer who had a suboptimal response to induction chemotherapy combined with immunotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07496190

• IMRT-only treatment for stage IB nasopharyngeal cancer without high-risk features

  This trial will test whether IMRT alone can control stage IB nasopharyngeal cancer without high-risk features in adults aged 18–70.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian · NCT07376603

• Toripalimab with three platinum-based induction chemotherapies for locally advanced nasopharyngeal carcinoma

  This trial tests whether adding toripalimab to one of three different platinum-based induction chemotherapy regimens before standard concurrent chemoradiotherapy can improve outcomes for adults with locally advanced nasopharyngeal carcinoma.

  Recruiting at 4 sites Phase 2 Sun Yat-sen University · Dongguan, Guangdong and 3 other locations · NCT07362979

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.